Liver Disease Diagnostics Market Analysis

Liver Disease Diagnostics Market Analysis

To get key market trends

  Download Free Sample

The market by disease type is segmented into hepatitis, cirrhosis, liver cancer, non-alcoholic fatty liver disease (NAFLD), and other disease types. The hepatitis segment accounted for majority revenue share and was valued at around USD 13.1 billion revenue in 2023.
 

• Chronic hepatitis B and C infections are major risk factors for developing hepatocellular carcinoma (HCC), a form of primary liver cancer. The growing prevalence of HCC focuses on the importance of early detection, monitoring and employing hepatitis and liver cancer diagnostics to improve patient outcomes in diagnostics. For instance, according to the North American Association of Central Cancer Registries (NAACCR), 41,210 new HCC cases were diagnosed in the U.S. in 2023.
   
• Moreover, hepatitis B infection in pregnant women can lead to the transmission of the virus to newborns. Screening and timely intervention are crucial to prevent mother-to-child transmission, emphasizing the need for effective hepatitis diagnostics in maternal and neonatal health.
   

Based on technique, the liver disease diagnostics market is categorized into imaging, liver biopsy, endoscopy, and laboratory tests. The laboratory tests segment dominated the market and accounted for over 38.1% market share in 2023.
 

• Routine liver function tests, including measures of liver enzymes (ALT, AST, ALP), bilirubin, and albumin, are essential for assessing the overall health of the liver. These tests are commonly prescribed in various clinical settings to screen for liver diseases, contributing to the consistent demand for laboratory testing.
   
• Additionally, liver disease testing is becoming more accurate, efficient, and rapid owing to consistent advances in laboratory diagnostic technology, such as automated analyzers, immunoassays, and molecular diagnostic techniques. Continuous advancement increases the capability of laboratory testing.
   

The liver disease diagnostics market by end-use is categorized into hospitals, laboratories, and other end-users. The hospitals segment accounted for over USD 20.8 billion revenue in 2023.
 

• Hospitals provide comprehensive care for patients with liver diseases, and diagnostics are a crucial component of this care. From routine screening to advanced diagnostics for complex cases, hospitals offer a wide range of liver disease diagnostic services.
   
• Furthermore, hospitals typically house advanced imaging facilities, such as CT scans, MRI, and ultrasound, which are essential for liver disease diagnostics. Additionally, hospitals perform liver biopsies and other invasive diagnostic procedures to obtain accurate information about liver health.
   

North America liver disease diagnostics market accounted for USD 16.2 billion revenue in 2023 and is estimated to witness substantial market expansion over the analysis timeline.
 

• North America has one of the world's highest obesity rates, that is a key risk factor for liver disease. The obesity pandemic increases the prevalence of disorders such as NAFLD and liver steatosis, thus, boosting the demand for liver disease diagnostics.
   
• Furthermore, the region has excellent healthcare infrastructure, including cutting-edge diagnostic centres and hospitals. The availability of advanced imaging technologies, laboratories, and specialised hepatology departments.